Accession Number:



Evaluation of Veriox as a Skin Decontamination Product after Dermal Exposure to the Nerve Agent VX

Corporate Author:

U.S. Army Medical Research Institute of Chemical Defense Aberdeen Proving Ground United States

Report Date:



Veriox R is a topical antimicrobial anti-infectivedisinfectant, which is under development for various uses to include medical device sterilization, advanced wound care, surface disinfection, a coating on medical products, hand sanitization, and veterinary wound care. The purpose of these experiments was to determine whether Veriox had efficacy as a decontamination product DC after skin exposure to the chemical warfare agent VX. This study compared the effectiveness of Veriox to Reactive Skin Decontamination Lotion RSDL when each was used as a DC product 2 min after dermal exposure to VX in hair-clipped, unanesthetized guinea pigs. Efficacy was established by generating VX dose-lethality curves for each DC product based on 24 survivallethality responses and calculating the VX dose at which 50 LD50 of animals died. The dermal LD50 of VX in Veriox-treated animals was 5959 micro gkg, which was 1.8 fold higher than the VX LD50 of 3380 micro gkg in RSDL-treated animals. Veriox was significantly p0.05 more effective than RSDL. Further studies with Veriox are needed to determine its ultimate usefulness as a skin DC product for military use.

Descriptive Note:

Technical Report,01 Jan 2016,31 Mar 2016



Distribution Statement:

Approved For Public Release;

File Size: